スギモト　ケン   Ken Sugimoto   杉本　研    所属   川崎医科大学  医学部 臨床医学　総合老年医学    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study.
掲載誌名	正式名：Pharmacogenomics 略　 称：Pharmacogenomics ISSNコード：17448042/14622416
掲載区分	国外
巻・号・頁	14(14),pp.1709-1721
著者・共著者	Kamide Kei, Asayama Kei, Katsuya Tomohiro, Ohkubo Takayoshi, Hirose Takuo, Inoue Ryusuke, Metoki Hirohito, Kikuya Masahiro, Obara Taku, Hanada Hironori, Thijs Lutgarde, Kuznetsova Tatiana, Noguchi Yuichi, Sugimoto Ken, Ohishi Mitsuru, Morimoto Shigeto, Nakahashi Takeshi, Takiuchi Shin, Ishimitsu Toshihiko, Tsuchihashi Takuya, Soma Masayoshi, Higaki Jitsuo, Matsuura Hideo, Shinagawa Tatsuo, Sasaguri Toshiyuki, Miki Tetsuro, Takeda Kazuo, Shimamoto Kazuaki, Ueno Michio, Hosomi Naohisa, Kato Jyouji, Komai Norio, Kojima Shunichi, Sase Kazuhiro, Miyata Toshiyuki, Tomoike Hitonobu, Kawano Yuhei, Ogihara Toshio, Rakugi Hiromi, Staessen Jan A, Imai Yutaka, ,
発行年月	2013/11
概要	BACKGROUND:Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB).METHODS:We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10(-4), we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine.RESULTS:SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication.CONCLUSION:Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.
DOI	10.2217/pgs.13.161
PMID	24192120